Lorusso Vito, Cinieri Saverio, Latorre Agnese, Porcu Luca, Del Mastro Lucia, Puglisi Fabio, Barni Sandro
UOC Oncologia Medica, Istituto Tumori Giovanni Paolo II, Bari, Italy.
Medical Oncology Division and Breast Unit, Ospedale A Perrino, Brindisi, Italy.
Future Oncol. 2017 May;13(11):971-978. doi: 10.2217/fon-2016-0530. Epub 2017 Feb 24.
Recent clinical, randomized and observational studies showed that eribulin, an analogous of Halichondrin B, was beneficial and well-tolerated in heavily pretreated metastatic breast cancer patients. Here, we aim to evaluate the effectiveness and safety of eribulin in taxane-refractory metastatic breast cancer patients.
PATIENTS & METHODS: In this subanalysis of the ESEMPIO study database, we selected 91 subjects with well-defined taxane refractoriness and complete data available.
41 patients (45.2%) showed clinical benefit; one complete response (2.2%) and 16 partial responses (17.6%) were observed. Median progression-free survival and median overall survival were 3.1 and 11.6 months, respectively. The most experienced adverse event was asthenia/fatigue (58%), followed by neutropenia (30%). The treatment-related toxicity led to eribulin-dose reduction in 19 patients and suspension in nine.
This study shows that eribulin is effective and well tolerated also in taxane-refractory patients in clinical practice.
近期的临床、随机和观察性研究表明，艾日布林（一种软海绵素B类似物）对经过多次治疗的转移性乳腺癌患者有益且耐受性良好。在此，我们旨在评估艾日布林在紫杉烷难治性转移性乳腺癌患者中的有效性和安全性。
在对ESEMPIO研究数据库的此次亚组分析中，我们选取了91例紫杉烷难治性明确且有完整可用数据的受试者。
41例患者（45.2%）显示出临床获益；观察到1例完全缓解（2.2%）和16例部分缓解（17.6%）。无进展生存期和总生存期的中位数分别为3.1个月和11.6个月。最常见的不良事件是乏力/疲劳（58%），其次是中性粒细胞减少（30%）。治疗相关毒性导致19例患者艾日布林剂量减少，9例患者停药。
本研究表明，在临床实践中，艾日布林对紫杉烷难治性患者也有效且耐受性良好。
